CML, FMS-like tyrosine kinase 3 (FLT3)-mutated AML and B-cell neoplasms are amongst the malignancies most responsive to KI treatment, including FDA approved drugs [73,74,75]. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.